Billy Ngasala, Mercy G Chiduo, Samwel Bushukatale, Bruno P Mmbando, Twilumba Makene, Erasmus Kamugisha, Maimuna Ahmed, Celine I Mandara, Filbert Francis, Muhidin K Mahende, Reginald A Kavishe, Florida Muro, Deus S Ishengoma, Renata Mandike, Fabrizio Molteni, Frank Chacky, Chonge Kitojo, George Greer, Dunstan Bishanga, Jasmine Chadewa, Ritha Njau, Marian Warsame, Bilali Kabula, Ssanyu S Nyinondi, Erik Reaves, Ally Mohamed
BACKGROUND: The use of artemisinin-based combination therapy (ACT) is recommended by the World Health Organization for the treatment of uncomplicated falciparum malaria. Artemether-lumefantrine (AL) is the most widely adopted first-line ACT for uncomplicated malaria in sub-Saharan Africa (SSA), including mainland Tanzania, where it was introduced in December 2006. The WHO recommends regular assessment to monitor the efficacy of the first-line treatment specifically considering that artemisinin partial resistance was reported in Greater Mekong sub-region and has been confirmed in East Africa (Rwanda and Uganda)...
April 6, 2024: Malaria Journal